Beta-blockers for the treatment of infantile haemangiomas in premature infants

IF 2.2 4区医学 Q2 DERMATOLOGY

Australasian Journal of Dermatology Pub Date : 2024-06-24 DOI:10.1111/ajd.14338

Lynn Chua Ting Ling MD, Mark Koh Jean Aan MD

引用次数: 0

Abstract

Beta-blockers have been established as a treatment of infantile haemangiomas (IH) since its serendipitous discovery for use in IH in 2008. However, data on the safety of these beta-blockers for use in IH in preterm infants are scarce. A retrospective study was performed to review the safety of oral propranolol and topical timolol in the treatment of IH in a cohort of preterm infants treated at our tertiary paediatric hospital. It was observed that there was an increased risk of adverse events amongst the preterm infants with chronic lung disease, retinopathy of prematurity and gastroesophageal reflux, when treated with oral propranolol.

查看原文本刊更多论文

β-受体阻滞剂治疗早产儿婴儿血管瘤。

自 2008 年偶然发现β-受体阻滞剂可用于治疗婴儿血管瘤（IH）以来，β-受体阻滞剂已被确定为治疗婴儿血管瘤的一种方法。然而，有关这些β-受体阻滞剂用于早产儿血管瘤安全性的数据却很少。我们开展了一项回顾性研究，对在我们的三级儿科医院接受治疗的早产儿队列中口服普萘洛尔和外用噻吗洛尔治疗 IH 的安全性进行了回顾。研究发现，在使用口服普萘洛尔治疗时，患有慢性肺病、早产儿视网膜病变和胃食管反流的早产儿发生不良事件的风险增加。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Australasian Journal of Dermatology 医学-皮肤病学

CiteScore

3.20

自引率

5.00%

发文量

186

审稿时长

6-12 weeks

期刊介绍： Australasian Journal of Dermatology is the official journal of the Australasian College of Dermatologists and the New Zealand Dermatological Society, publishing peer-reviewed, original research articles, reviews and case reports dealing with all aspects of clinical practice and research in dermatology. Clinical presentations, medical and physical therapies and investigations, including dermatopathology and mycology, are covered. Short articles may be published under the headings ‘Signs, Syndromes and Diagnoses’, ‘Dermatopathology Presentation’, ‘Vignettes in Contact Dermatology’, ‘Surgery Corner’ or ‘Letters to the Editor’.